An FDA advisory committee voted 6-6 plus one abstention on whether the FDA should approve Novo Nordisk's diabetes drug liraglutide. The panel centered its discussion on a type of thyroid tumor identified in animal trials that could develop into a more serious form of cancer in humans. Officials of Novo Nordisk did not comment on the panel's decision.

Related Summaries